Overview: NGS Neuropathy Panel Sequencing TestIntroduction: The NGS Neuropathy Panel Sequencing Test sequences neuropathy-related genes to diagnose hereditary neuropathy, causing numbness or weakness. Following 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected hereditary neuropathy, such as Charcot-Marie-Tooth disease or other peripheral neuropathies.
Other Names: Neuropathy NGS Assay, Peripheral Neuropathy Gene Panel.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Neuropathy sequencing began in the 1990s with peripheral nerve disorder research. NGS methods improved in the 2010s, enhancing diagnostic precision for hereditary neuropathies.
Purpose: Sequences neuropathy-related genes to diagnose hereditary neuropathy, guides treatment, and evaluates patients with numbness or weakness.
Test Parameters: 1. Neuropathy Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of numbness, weakness, or neuropathy symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document numbness, weakness, sensory loss, or family history of neuropathy. Include current medications, especially pain relievers or anticonvulsants.
Consent: Written consent required, detailing the tests purpose, hereditary neuropathy implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze neuropathy-related genes (e.g., PMP22, GJB1). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for hereditary neuropathy diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm hereditary neuropathy, guiding supportive care, physical therapy, or genetic counseling. Negative results may require nerve conduction studies.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Nerve conduction studies, EMG, or nerve biopsy to confirm hereditary neuropathy diagnosis.
Test Limitations: Not all neuropathy cases are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN Neuropathy Guidelines, 2023; Neurology, Reilly MM, 2022.
